PASADENA, Calif.--(BUSINESS WIRE)--Janus Pharmaceuticals Inc. (Janus), a company focused on the discovery and development of drugs to treat a variety of topical diseases, announced today the execution of license agreement with Nihon Nohyaku Co., Ltd.(NNC) (Tokyo, Japan), an agrochemical and pharmaceutical manufacturer, granting Janus for an exclusive development and sales of a novel antifungal drug “Luliconazole” in North America, Europe and South America.
